Handelsbanken Fonder AB Sells 4,200 Shares of Illumina, Inc. $ILMN

Handelsbanken Fonder AB decreased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 8.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 47,400 shares of the life sciences company’s stock after selling 4,200 shares during the quarter. Handelsbanken Fonder AB’s holdings in Illumina were worth $6,217,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of ILMN. Empowered Funds LLC grew its stake in shares of Illumina by 113.7% in the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock worth $737,000 after purchasing an additional 4,940 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in Illumina during the second quarter valued at $621,000. CW Advisors LLC bought a new stake in Illumina during the second quarter valued at $275,000. Marshall Wace LLP boosted its position in Illumina by 49.0% during the second quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock valued at $5,691,000 after acquiring an additional 19,618 shares during the last quarter. Finally, Cresset Asset Management LLC boosted its position in Illumina by 30.9% during the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock valued at $706,000 after acquiring an additional 1,748 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Price Performance

ILMN stock opened at $144.41 on Friday. The stock has a market capitalization of $21.85 billion, a PE ratio of 26.26, a price-to-earnings-growth ratio of 2.40 and a beta of 1.42. The company’s 50-day moving average is $130.45 and its 200-day moving average is $130.91. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. Illumina, Inc. has a 1 year low of $78.55 and a 1 year high of $155.53.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The company had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The business’s revenue was up 4.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Equities research analysts expect that Illumina, Inc. will post 5.2 EPS for the current fiscal year.

Insider Transactions at Illumina

In other news, Director Keith A. Meister sold 225,067 shares of the stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $145.55, for a total transaction of $32,758,501.85. Following the transaction, the director owned 3,604,441 shares of the company’s stock, valued at $524,626,387.55. This represents a 5.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Christensen Jakob Wedel sold 700 shares of the stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $139.04, for a total transaction of $97,328.00. Following the transaction, the senior vice president directly owned 15,056 shares in the company, valued at $2,093,386.24. This trade represents a 4.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 330,160 shares of company stock worth $48,028,308 in the last three months. Insiders own 2.90% of the company’s stock.

Analysts Set New Price Targets

ILMN has been the topic of a number of research analyst reports. Royal Bank Of Canada initiated coverage on shares of Illumina in a research report on Thursday, May 14th. They set an “outperform” rating and a $170.00 price target on the stock. Wall Street Zen cut shares of Illumina from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. JPMorgan Chase & Co. upped their price target on shares of Illumina from $120.00 to $125.00 and gave the company a “neutral” rating in a research report on Friday, May 1st. Guggenheim upped their price target on shares of Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Finally, UBS Group reaffirmed a “neutral” rating and set a $135.00 price target on shares of Illumina in a research report on Friday, February 6th. Seven equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $137.75.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.